anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent pharmacogenetic studies have advanced the gene coding for µ-opioid receptors (OPRM1) gene as a potential moderator of responses to naltrexone. The most widely studied polymorphism of the OPRM1 gene is the Asn40Asp single nucleotide polymorphism (SNP), a functional mutation thought to affect receptor activity such that the Asp40 variant binds β-endorphin three times stronger than the Asn40 allele. Recent studies have found that Asp40 carriers have a stronger striatal dopamine response to intravenous alcohol administration and report stronger feelings of alcohol reward. Findings from the COMBINE Study demonstrated that if treated with Medication Management alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared with only 54.8% of Asn40 homozygotes. While these findings are promising, studies have also highlighted allele frequency imbalance as a function of ethnicity such that the Asp40 allele frequency is approximately 20% in Caucasians, 5% in individuals of African Ancestry, and as high as 50% among individuals of East Asian descent. Therefore, to the extent to which this SNP moderates behavioral and clinical responses to NTX, ethnicity must be carefully considered in order to extend the findings from primarily Caucasian samples to ethnic minorities, such as Asian Americans. Preliminary work by our team has found that among individuals of East Asian descent, Asp40 carriers show greater NTX-induced blunting of alcohol craving as well as potentiation of the aversive effects of alcohol. This pilot study also found support for a gene dose-response, such that Asp40Asp individuals showed greater NTX responsivity than those with the Asn40Asp genotype. This study seeks to build upon these preliminary findings by testing heavy drinkers of East Asian descent across three OPRM1 genotypes (Asn40Asn, n = 30; Asn40Asp, n = 30, and Asp40Asp, n = 30). Participants will complete two double-blinded, counterbalanced alcohol infusion and self-administration sessions, one after taking NTX (50 mg/day) and one after taking matched placebo for five days. In each medication condition, participants will complete a functional neuroimaging task examining cue-induced craving for alcohol. This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of Asian descent, an ethnic group most likely to express the positive predictive allele (Asp40). The long-term objective of this research is to optimize alcoholism pharmacotherapy and to address health disparities by advancing pharmacogenetic studies in ethnic minority groups.
FIELD: medicine, microbiology, chemical-pharmaceutical industry. SUBSTANCE: method involves biomass culturing, biomass concentrating, addition of protective medium for drying, lyophilization of frozen product, mixing with a preliminary sterilized filling agent. The latter is used as a protective substance and energy source (lactose) for growth of bacteria B. bifidum. Then mixture is packaged into rigid detachable gelatin capsules followed by their placing into hermetic package and preparing the end product having degree of activity bifidobacterium at the level 2 x 10 8 , not less. EFFECT: improved method of preparing. 2 cl, 5 tbl, 1 ex
The invention discloses a traditional Chinese medicine containing red ginseng and a preparation method thereof. The traditional Chinese medicine containing red ginseng comprises, by mass, 80-100 parts of red ginseng, 40-50 parts of fleece-flower root, 15-35 parts of Radix Astragali, 25-40 parts of Chinese angelica, 40-60 parts of prepared rehmannia root, 20-30 parts of poria cocos, 35-45 parts of bighead atractylodes rhizome, 70-90 parts of dextrin and 3-7 parts of magnesium stearate. Red ginseng and Chinese angelica as raw materials do not contain hormones and antibiotics in Western medicines so that drug resistance is not produced. A study proves that the natural plants adopted by the preparation method have no obvious toxic or side effect, have high safety, can be absorbed easily, can produce effects fast, and are convenient for use. The traditional Chinese medicine containing red ginseng has effects of tonifying qi, nourishing yin, nourishing blood, generating body fluid, strengthening heart, strengthening stomach and calming nerves, can treat and prevent diseases such as internal lesion caused by overexertion and asthenic disease, reduced appetite, lassitude, regurgitation and emesis, diarrhea, lung vacuity cough and rapid respiration, spontaneous perspiration and heart-Yang collapse, palpitate with fear, forgetfulness, dizziness and headache, impotence and frequent micturition. The preparation method has a low cost and simple processes and can be used widely.
Vector Biodistribution (within the body) and Vector Shedding (excretion/secretion)

Nonclinical data

Biodistribution of HEMGENIX was evaluated after intravenous administration in healthy male mice and non-human primates (NHPs). The highest levels of vector DNA were detected in the liver and adrenal glands in both species. Vector DNA was also detected in all reproductive tissues examined (epididymis, seminal vesicles, and testes). In a mating study evaluating a predecessor of HEMGENIX, transmission of vector DNA to naïve female mice following mating with dosed males was not observed [see Nonclinical Toxicology (13.2)].

Clinical data

Following administration of the predecessor of HEMGENIX at doses of 5 ×1012 (N = 5) and 2 × 1013 gc/kg (N = 5) in a clinical study, the pharmacokinetics of vector DNA in blood and viral shedding in saliva, nasal secretions, semen, urine, and feces were characterized. Clearance of vector DNA as confirmed by 3 subsequent measurements below limit of detection (LOD), was achieved in all subjects at both dose levels from all the matrices except for semen, where clearance was achieved in 9/10 subjects. One subject was unable to produce semen due to a historical medical condition and, therefore, shedding from semen could not be assessed. The maximum time to clearance of vector DNA was 22 weeks for urine, 26 weeks for saliva and nasal secretions, 40 weeks for feces, 52 weeks for semen, and 159 weeks for blood.

Subsequently, the pharmacokinetics of vector DNA in blood, and viral shedding in semen following HEMGENIX administration was characterized in 2 clinical studies.

In an initial clinical study (N = 3), clearance of vector DNA from semen and blood (i.e., confirmed with 3 subsequent measurements below LOD of vector DNA) was achieved in 2/3 subjects, and in all subjects, respectively, after 3 years post-administration. One subject did not return the required number of semen samples to assess the shedding status as per the definition of 3 subsequent measurements below LOD of vector DNA.

In the clinical efficacy study (N = 54), a total of 56% (30/54) of subjects achieved absence of vector DNA from blood and 69% (37/54) from semen by Month 24. Several subjects did not return the required number of blood and semen samples to assess the shedding status as per the definition of 3 subsequent measurements below LOD of vector DNA. Considering results obtained from 2 available consecutive samples below LOD, a total of 40/54 (74%) and 47/54 (87%) subjects were identified to have reached absence of vector DNA from blood and semen, respectively, at 24 months post-administration.
FIELD: cosmetics. SUBSTANCE: method involves additionally introducing polyethylene glycol-115, triethylene glycol, sodium or potassium hydroxide, nitrate or chloride of lanthanum, cerium, praseodymium or neodymium in a given proportion to a cream having glycerol, ethyl alcohol and water. The ingredients are to be prepared separately and then mixed in series at the last stage. Intensive stirring is to be carried out during 1.5- 2.0 h at 60-70 C and later the produced cream temperature is lowered down to the room temperature. EFFECT: reliable protection of skin from being exposed to harmful effects of organophosphorous substances. 2 cl, 2 tbl
BACKGROUND: Many studies have demonstrated the association between intestinal microbiota and joint diseases. The "gut-joint axis" also has potential roles in chikungunya virus (CHIKV) infection. Pro-inflammatory arthritis after CHIKV infection might disrupt host homeostasis and lead to dysbacteriosis. This study investigated the characteristics of fecal and gut microbiota, intestinal metabolites, and the changes in gene regulation of intestinal tissues after CHIKV infection using multi-omics analysis to explore the involvement of gut microbiota in the pathogenesis of CHIKV infection.
RESULTS: CHIKV infection increases the systemic burden of inflammation in the GI system of infected animals. Moreover, infection-induced alterations in GI microbiota and metabolites may be indirectly involved in the modulation of GI and bone inflammation after CHIKV infection, including the modulation of inflammasomes and interleukin-17 inflammatory cytokine levels.
CONCLUSION: Our results suggest that the GI tract and its microbes are involved in the modulation of CHIKV infection, which could serve as an indicator for the adjuvant treatment of CHIKV infection. Video Abstract.
The LLLT phase will be done with an uninitiated 300-micron tip at 0.5 W in a CW. For this phase, the tip will be kept apart from the targeted tissue by 1mm in the scanning motion.
Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
A method for optimizing imaging protocols usage based on community voting includes a computer storing standard imaging protocol data associated with an imaging device type in a protocol database. The computer receives a request to modify the standard imaging protocol data. Next, the computer presents information from the request on a website accessible by a plurality of community members. Vote values are received from the community members via the website, each respective vote value selected from a range of values with a minimum value indicating rejection of the modified imaging protocol data and a maximum value indicating acceptance of the modified imaging protocol data. The computer then determines whether a consensus decision exists among the vote values. If the consensus decision exists, the computer determines whether to accept or reject the request to modify the standard imaging protocol data based on the consensus decision.
BACKGROUND: Isaacs' syndrome, also known as neuromyotonia or peripheral nerve hyperexcitability, is a rare disorder that affects the peripheral nervous system. Clinical findings include cramps, fasciculations, and myokymia; however, there are few reports of dental treatment for trismus.
CASE PRESENTATION: A patient with trismus due to Isaacs' syndrome experienced swelling and pain in the gingiva surrounding his right lower first molar. He was diagnosed with chronic apical periodontitis by a dentist near his home. However, the patient was informed that dental treatment and medication could not be administered because of the presence of Isaacs' syndrome, and he visited the Geriatric Dentistry and Perioperative Oral Care Center at Kyushu University Hospital 2 weeks later. The patient's painless mouth-opening distance (between incisors) was 20 mm at that time, and medication, including amoxicillin capsules and acetaminophen, was administered because the dental extraction forceps or endodontic instruments were difficult to insert into the oral cavity for treatment. Two months after his initial visit, the patient visited us complaining of pain in the same area. However, he had recently undergone plasmapheresis treatment in neurology to alleviate limited mouth opening and systemic myalgia, resulting in a pain-free mouth-opening distance of approximately 35 mm. During this temporary period in which he had no restriction in mouth opening, we performed tooth extraction and bridge restoration on the mandibular right first molar and created an oral appliance for sleep bruxism.
CONCLUSIONS: Plasmapheresis therapy transiently reduced trismus, rendering dental interventions feasible, albeit temporarily. This case report underscores the importance of close collaboration between neurologists and dentists who encounter similar cases while furnishing valuable insights to inform dental treatment planning.
A composition for treating hair and, in particular, for defrizzing hair, includes blackstrap molasses and honey. Essential oils can be added to the mixture. A method exists for making the composition. The method of making the composition includes heating the composition, possibly to a boil, cooling the composition, adding the essential oils, and mixing the imbibed composition. The composition is used in methods to treat hair. The composition treats hair by application or through heat treatments.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, hypervolemia, and hyperkalemia.

Too rapid infusion of hypertonic solutions may cause local pain and, rarely, vein irritation. Rate of administration should be adjusted according to tolerance. 

Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
Patients with early high-risk HR+HER2- breast cancer will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy as adjuvant therapy. During three years of follow-up, their relevant clinical data will be recorded.
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
Metabolic syndrome is a constellation of cardiovascular and metabolic risk factors including obesity, insulin resistance, hypertension and dyslipidemia. Coronary artery disease (CAD) is considerably linked with these risk factors. Oxidative stress has a major role in development of atherosclerosis that is believed as the most common pathologic process underlying CAD. The up-regulated gene-expression of free radical scavenging enzymes such as manganese superoxide dismutase (MnSOD) by members of the forkhead box O (FOXO) transcription factors is considered to be one of the paramount cell defensive mechanisms against oxidative damage. It is now well recognized that β-catenin binds to FOXOs during oxidative stress and acts as the pivotal mediator in canonical Wnt signaling, so that it translocates to the nucleus and interacts with the family of transcription factors T-cell factor/lymphoid enhancer factor (TCF/LEF), to regulate the expression of Wnt target genes. Recent evidence suggested that the canonical Wnt signaling plays a profound role in regulation of lipid metabolism and glucose homeostasis. Peroxisome proliferator-activated receptor delta (PPAR-δ) is one of the Wnt target genes which is believed to be operative in cardiometabolic protection. Interestingly, it has been demonstrated that impaired Wnt signaling pathway is contributed to inflammation, foam cell formation, and endothelial dysfunction which are recognized as atherosclerosis pathogenic factors. Resveratrol (RES) (3, 4´, 5 trihydroxystilbene), a natural polyphenol with antioxidant effects can be found in red grapes and its processed drinks (e.g. red wine), peanuts, pomegranates and mulberries.Increasing body of evidence suggest a protective role for RES against CAD, however the underlying mechanisms still remain to be elucidated. We perform this study on 10 metabolic syndrome patients with three-vessel CAD and 10 sex-aged matched (men with 40-55 years old) healthy subjects as controls. The effects of RES on β-Catenin, manganese superoxide dismutase (MnSOD), and peroxisome proliferator-activated receptor delta (PPAR-δ) expression are evaluated in peripheral blood mononuclear cells (PBMCs) of participants.
Chemical cpd. - contg. liposomes in which the chemical cpds. are enclosed in a pref. bimolecular layer of substances of formula X-Y (where X is a polar hydrophilic group and Y is a non-polar hydrophobic group) (e.g. phospholipids) to give ultra-small liposomes with a max. dia. of 1000 angstroms are produced by ultrasonic treatment of a disperse system, the closed phase of the system contg. insoln. the cpd. which is to be encapsulated and the disperse phase contg. the liposome-forming substance X-Y. The liposomes are extremely stable, affording protection to sensitive medicaments such as proteins, hormones, enzymes, vitamins etc. They are so small that they have outstanding penetration properties, enabling them to be readily pass through biological membranes. By suitable choice of the substance X-Y, the charge properties of the liposome wall can be controlled so that the liposome can be directed to a particular organ. By means of the liposomes, medicaments which have previously only been administered subutaneously or intravenously can now be administered orally.
Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 types of virus strains, including BV).
BACKGROUND: The epidemiological distribution of functional mitral regurgitation (FMR) in heart failure (HF) and mildly reduced ejection fraction (HFmrEF) patients and its impact on outcomes remains unclear. We attempt to investigate the prognosis of FMR in patients with HFmrEF.
METHODS: The HF center registry study is a prospective, single, observational study conducted at the Second Affiliated Hospital of Shenzhen University, where 2330 patients with acute HF (AHF) were enrolled and 890 HFmrEF patients were included in the analysis. The patients were stratified into three categories based on the severity of FMR: none/mild, moderate, and moderate-to-severe/severe groups. Subsequently, a comparison of the clinical characteristics among these groups was conducted, along with an assessment of the incidence of the primary endpoint (comprising all-cause mortality and readmission for HF) during a one-year follow-up period.
RESULTS: The one-year follow-up results indicated that the primary composite endpoint occurrence rates in the three groups were 23.5%, 32.9%, and 36.5%, respectively. The all-cause mortality rates in the three groups were 9.3%, 13.7%, and 16.4% respectively. Survival analysis demonstrated a statistically significant difference in the occurrence rates of the primary composite endpoint and all-cause mortality among the three groups (P < 0.05). Multifactor Cox regression revealed that moderate FMR and moderate-to-severe/severe FMR were independent risk factors for adverse clinical prognosis in HFmrEF patients, with hazard ratios and 95% confidence intervals of 1.382 (1.020-1.872, P = 0.037) and 1.546 (1.092-2.190, P = 0.014) respectively.
CONCLUSIONS: Moderate FMR and moderate-to-severe/severe FMR independently predict an unfavorable prognosis in patients with HFmrEF.
Disclosed are embodiments of methods and systems for predicting a health condition of a first human subject. The method comprises extracting a historical data including physiological parameters of second human subjects. Thereafter, a first distribution of a first physiological parameter is determined based on a marginal cumulative distribution of a rank transformed historical data. Further, a second distribution of a second physiological parameter is determined based on the first distribution and a first conditional cumulative distribution of the rank transformed historical data. Further, a latent variable is determined based on the first and the second distributions. Thereafter, one or more parameters of at least one bivariate distribution, corresponding to a D-vine copula, are estimated based on the latent variable. Further, a classifier is trained based on the D-vine copula. The classifier is utilizable to predict the health condition of the first human subject based on his/her physiological parameters.
PURPOSE: Evidence-based treatments for fatigue after brain injury are scarce and often not personalized. An approach to foster personalization is Experience Sampling Methodology (ESM), consisting of repeated daily measurements of fatigue and related factors in daily life. We investigated the feasibility and usability of a novel six-week ESM-based intervention for fatigue after brain injury.
MATERIALS AND METHODS: Ten individuals with acquired brain injury (six men; four women) aged between 36-70 years (M = 53.3, SD = 12.9) used a mHealth application for three days each week during six-weeks; seven completed the intervention. Momentary fatigue, activities, mood, worrying, and social context were assessed with ESM and participants received weekly personalized feedback by a therapist..
RESULTS: 56% of ESM-questionnaires (568/1008) were completed, providing detailed insights into individual fatigue patterns. No statistically significant decrease in response rate was found over the course of treatment. Qualitative feedback from participants revealed increased insight into factors underlying fatigue, and no problems with treatment duration or difficulties using the app. Five participants showed a decline in fatigue level during treatment.
CONCLUSIONS: This pilot study provides initial support for the feasibility and usability of this novel blended-care intervention, aimed at alleviating fatigue through personalized feedback and treatment strategies.
Pharmaceutical or cosmetic preparation comprises hyaluronic acid, a retinoid or its salts and/or derivatives, an oligosaccharide and a hyaluronic acid degradation inhibitor, in a medium. Independent claims are included for: (1) a product comprising the components of the preparation as a combination product for simultaneous, separate or systematic use to treat dermatological disorders; and (2) the preparation of the pharmaceutical or cosmetic preparation comprising either mixing the components or a first stage of preparation of an injectable solution comprising the mixture of hyaluronic acid with a medium and a second stage of preparation of a topical composition comprising the mixture of the retinoid, its salts and/or derivatives with an oligosaccharide and a hyaluronic acid degradation inhibitor with a medium. ACTIVITY : Dermatological. MECHANISM OF ACTION : Hyaluronidase inhibitor. The ability of the hyaluronic acid degradation inhibitor was tested against bovine hyaluronidase activity. The results showed that glycyrrhizine exhibited an inhibition activity with an IC 5 0 value of 400 mu m.